Abstract: An intermediate of the formula (I) wherein the radicals R1 are independently of one another methyl, ethyl or n-propyl, is suitable for preparing a compound of the formula (A) wherein X is a group of the formula (A-I) or (A-II), Y is C11-C17alkyl, and Z is a direct bond, —(CH2)8— or —CH2—S—CH2—. The compounds of the formula (A) are useful for stabilizing an organic material against thermal, oxidative or light induced degradation.

Abstract: An intermediate of the formula (I) wherein the radicals R1 are independently of one another methyl, ethyl or n-propyl, is suitable for preparing a compound of the formula (A) wherein X is a group of the formula (A-I) or (A-II), Y is C11-C17alkyl, and Z is a direct bond, —(CH2)8— or —CH2—S—CH2—. The compounds of the formula (A) are useful for stabilizing an organic material against thermal, oxidative or light induced degradation.

Abstract: Disclosed herein is a compound of the formula (I), wherein one or two radicals of the radicals R1 are independently of one another C1-C20alkyloxy or C3-C12cycloalkyloxy and the remaining radicals R1 are independently of one another hydrogen, C1-C20alkyl or C3-C12cycloalkyl; the radicals R0 and R2 are independently of one another hydrogen, C1-C20alkyl, C3-C12cycloalkyl or a group of the formula (II-a) with R3 being hydrogen, C1-C20alkyl, C3-C12cycloalkyl, C1-C20alkyloxy or C3-C12cycloalkyloxy; Y is C2-C12alkylene; m is 0 or 1; n is 1, 2 or 3; when n is 1, X is hydrogen, C1-C20alkyl, C3-C12cycloalkyl or a group of the formula (II-a); when n is 2, X is C2-C12alkylene; when n is 3, X is a group N(Z—)3 with Z being C2-C12alkyl.

Abstract: Disclosed herein is a compound of the formula (I), wherein one or two radicals of the radicals R1 are independently of one another C1-C20alkyloxy or C3-C12cycloalkyloxy and the remaining radicals R1 are independently of one another hydrogen, C1-C20alkyl or C3-C12cycloalkyl; the radicals R0 and R2 are independently of one another hydrogen, C1-C20alkyl, C3-C12cycloalkyl or a group of the formula (II-a) with R3 being hydrogen, C1-C20alkyl, C3-C13cycloalkyl, C1-C20alkyloxy or C3-C12cycloalkyloxy; Y is C2-C12alkylene; m is 0 or 1; n is 1, 2 or 3; when n is 1, X is hydrogen, C1-C20alkyl, C3-C12cycloalkyl or a group of the formula (II-a); when n is 2, X is C2-C12alkylene; when n is 3, X is a group N(Z—)3 with Z being C2-C12alkyl.

Abstract: A compound of the formula (I) wherein m and n are independently of one another a number from 1 to 50; the ratio of m/n is 1:10 to 10:1, the recurring units X can have the same definition or different definitions, the recurring units Y can have the same definition or different definitions and the recurring units X and Y can have a random, alternating or block distribution; the recurring unit X is a group of the formula (I-a) and the recurring unit Y is a group of the formula (I-b) the radicals R1 independently of one another are C1-C12alkyl or C3-C12cycloalkyl; the radicals R2 and R4 are independently of one another C12-C30alkyl; the radicals R3 are independently of one another hydrogen, C1-C12alkyl or C3-C12cycloalkyl.

Abstract: A compound of the formula (I), wherein one or two radicals of the radicals R1 are independently of one another C1-C20alkyloxy or C3-C12cycloalkyloxy and the remaining radicals R1 are independently of one another hydrogen, C1-C20alkyl or C3-C12cycloalkyl; the radicals R0 and R2 are independently of one another hydrogen, C1-C20alkyl, C3-C12cycloalkyl or a group of the formula (II-a) with R3 being hydrogen, C1-C20alkyl, C3-C12cycloalkyl, C1-C20alkyloxy or C3-C12cycloalkyloxy; Y is C2-C12alkylene; m is 0 or 1; n is 1, 2 or 3; when n is 1, X is hydrogen, C1-C20alkyl, C3-C12cycloalkyl or a group of the formula (II-a); when n is 2, X is C2-C12alkylene; when n is 3, X is a group N(Z—)3 with Z being C2-C12alkyl.

Abstract: A composition, which comprises a) an organic material susceptible to oxidative, thermal or light-induced degradation; and b) a compound of formula I (Formula I) (I) where R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are independently from each other H, C1-C8-alkyl, C4-C8-cycloalkyl, phenyl, C1-C4-alkoxy or halogen; n is 1, 2, 3, or 4; and when n is 1 A is —C(=0)-OR?1, —C(=0)-N(R?2)(R?3), —CN, phenyl, which is unsubstituted or substituted by one or more C1-C8-alkyl, C4-C8-alkoxy, C5-C7-cycloalkyl or halogen, —H or —S02-phenyl; when n is 2 A is —C(=0)-0-Z1—O—C(=0)-, —C(=0)-N(R?1)—Z2—N(R?2)—C(=0)- or piperazine-N,N?-biscarbonyl.

Abstract: A composition, which comprises a) an organic material susceptible to oxidative, thermal or light-induced degradation; and b) a compound of formula I (Formula I) (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are independently from each other H, C1-C8-alkyl, C4-C8-cycloalkyl, phenyl, C1-C4-alkoxy or halogen; n is 1, 2, 3, or 4; and when n is 1 A is —C(=0)-OR?1, —C(=0)-N(R?2)(R?3), —CN, phenyl, which is unsubstituted or substituted by one or more C1-C8-alkyl, C4-C8-alkoxy, C5-C7-cycloalkyl or halogen, —H or —S02-phenyl; when n is 2 A is —C(=0)-O—Z1—O—C(=0)-, —C(=0)-N(R?1)—Z2—N(R?2)—C(=0)- or piperazine-N,N?-biscarbonyl.

Abstract: A composition, which comprises a) an organic material susceptible to oxidative, thermal or light-induced degradation; and b) a compound of formula I (Formula I) (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are independently from each other H, C1-C8-alkyl, C4-C8-cycloalkyl, phenyl, C1-C4-alkoxy or halogen; n is 1, 2, 3, or 4; and when n is 1 A is —C(=0)-OR?1, —C(=0)-N(R?2)(R?3), —CN, phenyl, which is unsubstituted or substituted by one or more C1-C8-alkyl, C4-C8-alkoxy, C5-C7-cycloalkyl or halogen, —H or —S02-phenyl; when n is 2 A is —C(=0)-O—Z1—O—C(=0)-, —C(=0)-N(R?1)—Z2—N(R?2)—C(=0)- or piperazine-N,N?-biscarbonyl.

Abstract: A compound of the formula (I) wherein m and n are independently of one another a number from 1 to 50; the ratio of m/n is 1:10 to 10:1, the recurring units X can have the same definition or different definitions, the recurring units Y can have the same definition or different definitions and the recurring units X and Y can have a random, alternating or block distribution; the recurring unit X is a group of the formula (I-a) and the recurring unit Y is a group of the formula (I-b) the radicals R1 independently of one another are C1-C12alkyl or C3-C12cycloalkyl; the radicals R2 and R4 are independently of one another C12-C30alkyl; the radicals R3 are independently of one another hydrogen, C1-C12alkyl or C3-C12cycloalkyl.

Abstract: A compound of the formula (I), wherein one or two radicals of the radicals R1 are independently of one another C1-C20alkyloxy or C3-C12cycloalkyloxy and the remaining radicals R1 are independently of one another hydrogen, C1-C20alkyl or C3-C12cycloalkyl; the radicals R0 and R2 are independently of one another hydrogen, C1-C20alkyl, C3-C12cycloalkyl or a group of the formula (II-a) with R3 being hydrogen, C1-C20alkyl, C3-C12cycloalkyl, C1-C20alkyloxy or C3-C12cycloalkyloxy; Y is C2-C12alkylene; m is 0 or 1; n is 1, 2 or 3; when n is 1, X is hydrogen, C1-C20alkyl, C3-C12cycloalkyl or a group of the formula (II-a); when n is 2, X is C2-C12alkylene; when n is 3, X is a group N(Z—)3 with Z being C2-C12alkyl

Abstract: An intermediate of the formula (I) wherein the radicals R1 are independently of one another methyl, ethyl or n-propyl, is suitable for preparing a compound of the formula (A) wherein X is a group of the formula (A-I) or (A-II), Y is C11-C17alkyl, and Z is a direct bond, —(CH2)8— or —CH2—S—CH2—. The compounds of the formula (A) are useful for stabilizing an organic material against thermal, oxidative or light induced degradation.

Abstract: The present invention is directed to new crystalline forms of Atorvastatin calcium (2:1), referred to hereinafter as polymorphic Forms X, A, B1, B2, C, D and E. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.

Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous form.

Abstract: The present invention concerns coloring keratin fibers, especially human hair, with colored metal complexes.

Abstract: Diols of the formula I: or corresponding polymers wherein R1 has been integrated into a polymeric backbone, wherein n ranges from (1) to (4); X is a divalent linking group selected from the group consisting of ether, ester, amino and amido groups; R1 is an n-valent hydrocarbon residue containing at least one reactive group selected from the group consisting of carbon-carbon double or triple bonds and silyl groups; R2, R3 and R4 independently are hydrogen or C1-C4alkyl; are conveniently prepared by treatment of an epoxide of the formula II wherein all residues and the index n are as defined for formula I, or a corresponding polymer, with an epoxide hydrolase, e.g. from lyophilized cells of Aspergillus niger.

Abstract: Anti-microbial compositions comprising certain imidazolium ionic liquids and non-ionic or anionic surfactants and methods of using said compositions in the preservation of personal care and cosmetic applications are provided.

Abstract: The present invention is directed to new crystalline forms of Atorvastatin calcium (2:1), referred to hereinafter as polymorphic Forms X, A, B1, B2, C, D and E. The present invention also is directed to crystalline Form A of Atorvastatin calcium (2:1) that is stable against the formation of the AED impurity. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.

Abstract: The present invention is directed to new crystalline forms of Pitavastatin hernicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous form.

Abstract: The present invention relates to an improved process for the preparation of phenolic carboxylic acid derivatives catalysed by biocatalytic esterification, transesterification or amidation of a corresponding lower alkyl ester. Biocatalysis is performed in the presence of suitable enzymes, e.g. hydrolases, especially esterases, amidases, lipases and proteases.